DYN — Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 192
- Website: https://www.dyne-tx.com
Latest SEC filings for DYN
- 8-K — 2026-09-29
- SCHEDULE 13G/A — 2026-08-13
- SCHEDULE 13G/A — 2026-08-13
- SCHEDULE 13G/A — 2026-08-06
- 10-Q — 2026-07-29
- 8-K — 2026-07-29
- 8-K — 2026-07-22
- 424B5 — 2026-07-22
- 424B5 — 2026-07-22
- 424B5 — 2026-07-21
Latest DYN news
- — Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (globenewswire.com)
Educational tool only — not investment advice.